Achieve Life Sciences Inc. is a late-stage specialty pharmaceutical company dedicated to combating the global smoking health epidemic and nicotine addiction through the development and commercialization of cytisinicline. Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors in the brain, helping to reduce nicotine withdrawal symptoms and cravings, positioning it as a potential treatment for smoking cessation and nicotine dependence, including e-cigarette and vaping cessation. The company operates within the biotechnology sector of healthcare, focusing on innovative therapies to address nicotine addiction, a leading cause of preventable death worldwide. Achieve Life Sciences Inc. pursues regulatory approvals and partnerships for manufacturing to support commercialization efforts in key markets. Headquartered in Bothell, Washington, United States, the company emphasizes advancing cytisinicline as a widely available treatment option for individuals seeking to quit nicotine products.